
High Court continues Ribociclib case after petitioner's death
The story in brief
The original petitioner died during litigation, prompting the High Court to continue proceedings suo motu due to public interest. The case, concerning Ribociclib's high cost and patent protection, has been listed 57 times without final hearing, with a hearing scheduled for July 15, 2026. The Working Group on Access to Medicines and Treatment highlights the devastating human cost of judicial delays in accessing lifesaving drugs.